The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Inducing and exploiting vulnerabilities for the treatment of liver cancer
Open accessAbstract
Liver cancer remains difficult to treat, owing to a paucity of drugs that target critical dependencies 1,2; broad-spectrum kinase inhibitors such as sorafenib provide only a modest benefit to patients with hepatocellular carcinoma 3. The induction of senescence may represent a strategy for the treatment of cancer, especially when combined with a second drug that selectively eliminates senescent cancer cells (senolysis)4,5. Here, using a kinome-focused genetic screen, we show that pharmacological inhibition of the DNA-replication kinase CDC7 induces senescence selectively in liver cancer cells with mutations in TP53. A follow-up chemical screen identified the antidepressant sertraline as an agent that kills hepatocellular carcinoma cells that have been rendered senescent by inhibition of CDC7. Sertraline suppressed mTOR signalling, and selective drugs that target this pathway were highly effective in causing the apoptotic cell death of hepatocellular carcinoma cells treated with a CDC7 inhibitor. The feedback reactivation of mTOR signalling after its inhibition 6 is blocked in cells that have been treated with a CDC7 inhibitor, which leads to the sustained inhibition of mTOR and cell death. Using multiple in vivo mouse models of liver cancer, we show that treatment with combined inhibition of of CDC7 and mTOR results in a marked reduction of tumour growth. Our data indicate that exploiting an induced vulnerability could be an effective treatment for liver cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescence induction by inhibition of DNA replication kinase CDC7 has also been paired with a senolytic that disrupts mTOR signaling, inducing apoptosis in senescent human liver cancer cells and improving survival in mouse models of HCC (Wang et al. 2019).”
From Senescence and the SASP: many therapeutic avenues (2020) · cites this paper as Wang et al. 2019
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, many of the genes have been denoted as possible therapeutic targets in a variety of epithelial-based cancers, such as CDC7 in oral squamous carcinoma30 and liver cancer31, ATP1B3 in gastric cancer32, and FKBP14 in ovarian cancer33.”
From Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature (2023) · cites this paper as [31]
The cited source says what the claim attributes to it.
In the citing paper
“In a mouse model of liver cancer, the mTOR inhibitor AZD8055 also showed senolytic potential against cancer cells with senescence induced by small- molecule inhibitors of CDC7 (ref. 207 ) .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [207]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Elevated expression of p16 in melanocytes156 and epidermal and dermal cells157,158 is associated with human aging.”
From Guidelines for minimal information on cellular senescence experimentation in vivo (2024) · cites this paper as [156]
Experimental — accuracy not yet measuredIn the citing paper
“Based on the preclinical experimental evidence enumerated here, approaches based on the induction of senescence in large fraction of tumors have the potential to enter the realm of the clinical practice, even more if combined with adjuvant immunotherapy or senolytic therapy to remove potentially harmful senescent escaper variants, as recently proposed.189,202,203”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [202]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Self-citationThe comet assay: a method to measure DNA damage in individual cells
Olive, P. L., & Banáth, J. P. (2006) · Nature Protocols · doi:10.1038/nprot.2006.5 · Cited by 1,845
Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
Chang, J., Wang, Y., Shao, L., Laberge, R.-M., Demaria, M., Campisi, J., Janakiraman, K., Sharpless, N. E., Ding, S., Feng, W., et al. (2016) · Nature Medicine · doi:10.1038/nm.4010 · Cited by 1,819
Genetic landscape and biomarkers of hepatocellular carcinoma
Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325
Cited by
Sorted by citations
Items 201–300 of 432
Recent Advances in Senolysis for Age-Related Diseases
Aratani, S., & Nakanishi, M. (2023) · Physiology · doi:10.1152/physiol.00003.2023 · Cited by 16
Chen, M., Chen, W., Sun, S., Lu, Y., Wu, G., Xu, H., Yang, H., Li, C., He, W., Xu, M., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.08.034 · Cited by 16
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma
Mulero‐Sánchez, A., Ramirez, C. F. A., du Chatinier, A., Wang, H., Koomen, S. J. I., Song, J., de Groot, M. H. P., Lieftink, C., Bosma, A. R., Burylo, A. M., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13377 · Cited by 14
Self-citationMontuori, G., Tu, F., Qin, D., Schmargon, R., Rodriguez-Fos, E., Helmsauer, K., Hui, H., Mandal, S., Purshouse, K., Fankhänel, L., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1738 · Cited by 15
The two facets of gp130 signalling in liver tumorigenesis
Schmidt‐Arras, D., Galun, E., & Rose‐John, S. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00861-0 · Cited by 15
Cellular Senescence, a Novel Area of Investigation for Metastatic Diseases
Faggioli, F., Velarde, M. C., & Wiley, C. D. (2023) · Cells · doi:10.3390/cells12060860 · Cited by 15
Yang, C., Tiwari, S. K., Guo, L., An, G., Zheng, H., Huang, J., Jiang, L., Bai, Z., Zhu, Y., & Wang, N. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1110909 · Cited by 15
Wu, T., Yang, Z., Chen, W., Jiang, M., Xiao, Z., Su, X., Jiao, Z., Yu, Y., Chen, S., Song, M., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01571-2 · Cited by 17
Gao, Y. J., Hu, Y., Liu, Q., Li, X., Li, X., Kim, C., James, T. D., Li, J., Chen, X., & Guo, Y. (2021) · Angewandte Chemie · doi:10.1002/ange.202101278 · Cited by 16
The Potent and Paradoxical Biology of Cellular Senescence in Cancer
Romesser, P. B., & Lowe, S. W. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-124434 · Cited by 15
Zhang, S. (2022) · Journal of Oncology · doi:10.1155/2022/7609676 · Cited by 14
Chen, J., Chen, X., Li, T., Wang, L., & Lin, G. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108866 · Cited by 14
Self-citationXu, D., Yang, H., Schmid, R. A., & Peng, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.579464 · Cited by 14
Stromal senescence contributes to age-related increases in cancer
Ye, J., Melam, A., & Stewart, S. A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00840-9 · Cited by 16
Cellular Senescence in Liver Cancer: How Dying Cells Become “Zombie” Enemies
Gazzillo, A., Volponi, C., Soldani, C., Polidoro, M. A., Franceschini, B., Lleò, A., Bonavita, E., & Donadon, M. (2023) · Biomedicines · doi:10.3390/biomedicines12010026 · Cited by 14
CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer
Liu, S., Deng, P., Yu, Z., Hong, J. H., Gao, J., Huang, Y., Xiao, R., Yin, J., Zeng, X., Sun, Y.-C., et al. (2024) · Advanced Science · doi:10.1002/advs.202403782 · Cited by 13
Pogacar, Z., Johnson, J. L., Krenning, L., De Conti, G., Jochems, F., Lieftink, C., Velds, A., Wardak, L., Groot, K., Schepers, A., et al. (2022) · PLOS ONE · doi:10.1371/journal.pone.0273182 · Cited by 13
Self-citationNutritional Niches of Cancer Therapy-Induced Senescent Cells
Llop‐Hernández, À., Verdura, S., Cuyàs, E., & Menéndez, J. A. (2022) · Nutrients · doi:10.3390/nu14173636 · Cited by 13
Shi, H., Xiao, M., Li, Y., Liu, X., Na, J., Liang, C., Hua, J., Meng, Q., Wei, M., Wang, W., et al. (2025) · Theranostics · doi:10.7150/thno.112633 · Cited by 12
Self-citationCarpenter, V. J., Saleh, T., Chakraborty, E., Lee, S. M., Murray, G. F., Reed, J. C., Souers, A. J., Faber, A. C., Harada, H., & Gewirtz, D. A. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116385 · Cited by 12
Zhang, G., Xiao, Y., Liu, H., Wu, Y., Xue, M., & Li, J. (2024) · Immunobiology · doi:10.1016/j.imbio.2024.152841 · Cited by 12
Oxymatrine Inhibits Liver Cancer Progression by Regulating SIRT1/YY1/GPX4 Axis-Mediated Ferroptosis
Hu, J., Zhang, F., Qin, X., Nong, X., Shi, X., Zhou, X.-H., & Qin, Y. (2024) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.4c00208 · Cited by 12
At the Crossroads of Life and Death: The Proteins That Influence Cell Fate Decisions
Dhokia, V., Moss, J. A. Y., Macip, S., & Fox, J. L. (2022) · Cancers · doi:10.3390/cancers14112745 · Cited by 13
Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells
Sun, C., Talukder, M., Cao, D., & Chen, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.829759 · Cited by 12
Bubble Bubble, Senescent Cells Are a Cauldron of Tumor Trouble
Wiley, C. D. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1811 · Cited by 12
Efficacy and safety of Brucea javanica oil emulsion for liver cancer
Luo, D., Hou, D., Wen, T., Feng, M., & Haiming, Z. (2020) · Medicine · doi:10.1097/md.0000000000023197 · Cited by 12
Liu, X., Qu, H., Li, J., Sun, X., Wang, Z., Wang, D., Bai, X., & Li, X. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1584811 · Cited by 14
Elmetwalli, A., Nageh, A., Youssef, A. I., Youssef, M., Ahmed, M. A. E.-R., Noreldin, A. E., & El-Sewedy, T. (2023) · Medical Oncology · doi:10.1007/s12032-023-02250-z · Cited by 11
Liu, L., Liu, Z., Meng, L., Li, L., Gao, J., Yu, S., Hu, B., Yang, H., Guo, W., & Zhang, S. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.766609 · Cited by 11
Zhang, H., Zhao, L., Ren, P., & Sun, X. (2023) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2023.2193776 · Cited by 11
Okamura, K., Suzuki, T., & Nohara, K. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115259 · Cited by 11
Repurposing the Antidepressant Sertraline: A Systematic Scoping Review of Its Anticancer Mechanisms
Blum, C., Dohrmann, M., McCarthy, L., McMenamin, M., & O’Callaghan, L. A. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70168 · Cited by 10
Zhang, L., & Wang, X. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02761-w · Cited by 10
Jankelow, A. M., Almeida-Porada, G. D., Atala, A., Sawyer, S. W., & Porada, C. D. (2025) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szaf055 · Cited by 11
Cellular senescence in cancer: Friend or fraud?
Chen, Q., Liu, J., Wu, J., Xiang, X., Zhou, X., Mi, J., Wei, J., Zou, X., & Wu, A. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101363 · Cited by 15
Abdelmoaty, A. A. A., Chen, J., Zhang, K., Wu, C., Li, Y., Li, P., & Xu, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1422363 · Cited by 10
Inflammasome protein scaffolds the DNA damage complex during tumor development
Shen, C. X., Pandey, A., Tuipulotu, D. E., Mathur, A., Liu, L., Yang, H., Adikari, N. K., Ngo, C., Jing, W., Feng, S., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01988-6 · Cited by 13
Gao, F., Yang, J., Geng, Y., Liu, B., Zhang, R., & Zhang, M. (2021) · Chemical Papers · doi:10.1007/s11696-021-01509-x · Cited by 10
Schepers, A. G., Jochems, F., Lieftink, C., Wang, L., Pogacar, Z., de Oliveira, R. L., Conti, G. D., Beijersbergen, R. L., & Bernards, R. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0146 · Cited by 11
Self-citationZhang, L., Hong, J., Chen, W., Zhang, W., Liu, X., Lu, J., Tang, H., Yang, Z., Zhou, K., Xie, H., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.80351 · Cited by 10
Nanosystem Delivers Senescence Activators and Immunomodulators to Combat Liver Cancer
Gong, K., Jiao, J., Wu, Z., Wang, Q., Liao, J., Duan, Y., Lin, J., Yu, J., Sun, Y., Zhang, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202308310 · Cited by 9
Lorenzo‐Martín, L. F., Menacho-Márquez, M., & Bustelo, X. R. (2020) · Cancers · doi:10.3390/cancers12092498 · Cited by 10
Lu, D., Yu, L., Chen, Z., Chen, M., Lei, Z., Guo, H., Wang, X., Zhang, Y., Xu, T., Wang, H., et al. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01106 · Cited by 10
Identification of Sorafenib as a Treatment for Type 1 Diabetes
Zeng, Q., Song, J., Wang, D., Sun, X., Xiao, Y., Zhang, H., Xiao, Y., Zhou, Z., & Deng, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.740805 · Cited by 10
EFNA4-enhanced deubiquitination of SLC7A11 inhibits ferroptosis in hepatocellular carcinoma
Zhong, X., Zhu, Z., Du, Y., Long, L., Xie, Z., Zhang, Y., Yao, H., Lin, J., & Chen, F. (2024) · APOPTOSIS · doi:10.1007/s10495-024-02042-4 · Cited by 9
Wang, Z., Chen, C., Ai, J., Gao, Y., Wang, L., Xia, S., Jia, Y., & Qin, Y. (2025) · MedComm · doi:10.1002/mco2.70048 · Cited by 12
Self-citationOsalmid sensitizes clear cell renal cell carcinoma to navitoclax through a STAT3/BCL-XL pathway
Xue, Y., Chen, T., Ma, Z., Pu, X., Xu, J., Zhai, S., Du, X., Ji, Y., Simon, M. C., Zhai, W., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217514 · Cited by 9
Splicing factor SF3B4 acts as a switch in cancer cell senescence by regulating p21 mRNA stability
Kang, D., Sung, J. Y., Hwang, H. J., Baek, Y., Kim, M., Lim, G.-E., Kim, Y.-N., Cha, J., & Lee, J. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217530 · Cited by 11
Liu, L., Wang, Q., Wu, L., Zhang, L., Huang, Y., Yang, H., Guo, L., Fang, Z., & Wang, X. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02949-z · Cited by 9
Qu, X., Wu, P., Duan, K., Wang, G., Gao, L.-L., Guo, Y., Zhang, J., & Shi, D. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.109681 · Cited by 9
Huang, F., Shi, X., Hu, M. X., Yan, H., Li, X., Ding, Y., Zheng, X., Cai, X., Dai, S., Xia, Q., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176493 · Cited by 9
Impact and potential value of immunosenescence on solid gastrointestinal tumors
Zhang, T., Wen, R., Fan, H., Yu, Y., Jia, H., Peng, Z., Zhou, L., Yu, G., & Zhang, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1375730 · Cited by 8
Cellular senescence in the cancer microenvironment
Meguro, S., & Nakanishi, M. (2025) · The Journal of Biochemistry · doi:10.1093/jb/mvaf001 · Cited by 7
Lemay, S.-E. S., Mougin, M., Sauvaget, M., Kabbout, R. E., Valasarajan, C., Yamamoto, K., Martineau, S., Pelletier, A., Bilodeau, C., Grobs, Y., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.101964 · Cited by 8
Regulatory Roles of Exosomes in Aging and Aging-Related Diseases
Xiao, N., Li, Q., Liang, G., Qian, Z., Lin, Y., Zhang, H., Fu, Y., Yang, X. M., Zhang, C., Yang, J., et al. (2025) · Biogerontology · doi:10.1007/s10522-025-10200-7 · Cited by 8
Targeting Senescence in Oncology: An Emerging Therapeutic Avenue for Cancer
Meguro, S., Makabe, S., Yaginuma, K., Onagi, A., Tanji, R., Matsuoka, K., Hoshi, S., Koguchi, T., Kayama, E., Hata, J., et al. (2025) · Current Oncology · doi:10.3390/curroncol32080467 · Cited by 8
Combination therapy for HCC: from CRISPR screening to the design of clinical therapies
Wang, Y., Kui, L., & Wang, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00775-1 · Cited by 8
Xu, L., Wu, H., Pan, J., Chen, Z., & Du, L. (2022) · Journal of Oncology · doi:10.1155/2022/2313416 · Cited by 8
Wang, H., Tao, Y., Han, J., Shen, J., Mu, H., Wang, Z., Wang, J., Jin, X., Zhang, Q., Yang, Y., et al. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00967-1 · Cited by 9
Taranto, D., Ramirez, C. F. A., Vegna, S., de Groot, M. H. P., de Wit, N., Baalen, M. V., Klarenbeek, S., & Akkari, L. (2021) · Current Protocols · doi:10.1002/cpz1.147 · Cited by 8
Self-citationDbf4-Dependent Kinase: DDK-ated to post-initiation events in DNA replication
Dolson, A., Sauty, S. M., Shaban, K., & Yankulov, K. (2021) · Cell Cycle · doi:10.1080/15384101.2021.1986999 · Cited by 10
Tegaserod maleate exhibits antileukemic activity by targeting TRPM8
Xie, X., Yang, W., Zhang, W., Qiu, Y., Qiu, Z., Wang, H., Hu, Y., Li, Y., Zhou, X., Li, L., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113566 · Cited by 8
Could senescence phenotypes strike the balance to promote tumor dormancy?
Chiu, F.-Y., Kvadas, R. M., Mheidly, Z., Shahbandi, A., & Jackson, J. G. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10089-z · Cited by 8
Rigolet, M., Buisine, N., Scharwatt, M., Duvernois‐Berthet, E., Buchholz, D. R., & Sachs, L. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213715 · Cited by 7
Xu, Y., Qi, W., Zheng, C., Li, Y., Lu, Z., Guan, J., Lu, C., & Zhao, B. (2023) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjad066 · Cited by 7
When therapy-induced senescence meets tumors: A double-edged sword: A review
Liu, K., Huang, H., Zhang, M., Chen, S., Yang, Y., Fang, C., & Zhong, X. (2025) · Medicine · doi:10.1097/md.0000000000042886 · Cited by 9
Chava, S., Wajapeyee, N., Malvi, P., & Gupta, R. (2022) · iScience · doi:10.1016/j.isci.2022.104752 · Cited by 7
Zhang, G., Xiao, Y., Zhang, X., Fan, W., Zhao, Y., Wu, Y., Wang, H., & Li, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.978050 · Cited by 7
Xu, A.-X., Zhao, Z., Zhu, L. Y., Zhang, Y., Li, Y., Wei, Y., Zhang, B., Jiang, B., Gao, T.-Z., Li, M., et al. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i40.4380 · Cited by 7
Proteomics efforts for hepatocellular carcinoma drug development
Jia, D., Jiang, Z., Cui, M., & Ding, X. (2024) · Clinical Cancer Bulletin · doi:10.1007/s44272-024-00027-7 · Cited by 7
Are we ready for targeted therapy combinations in HCC?
Cinnamon, E., & Pikarsky, E. (2020) · Gut · doi:10.1136/gutjnl-2019-319780 · Cited by 7
Ras/MAPK signalling intensity defines subclonal fitness in a mouse model of hepatocellular carcinoma
Lozano, A., Souche, F.-R., Carine Chavey, A., Dardalhon, V., Ramirez, C. F. A., Vegna, S., Desandré, G., Riviere, A., Aabidine, A. Z. E., Fort, P., et al. (2023) · eLife · doi:10.7554/elife.76294 · Cited by 7
Self-citationLu, X., Yuan, F., Qiao, L., Liu, Y., Gu, Q., Qi, X., Li, J., Li, D., & Liu, M. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116099 · Cited by 8
Targeting senescent cells and tumor therapy (Review)
Wang, Z., Gao, J., Liu, H., Ohno, Y., & Xu, C. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4705 · Cited by 8
Liu, Y., Xue, M., Cao, D., Qin, L., Wang, Y., Miao, Z., Wang, P., Hu, X., Shen, J., & Xiong, B. (2021) · Genomics · doi:10.1016/j.ygeno.2021.02.017 · Cited by 7
Chaib, S., Lopez-Dominguez, J. A., Lalinde-Gutiérrez, M., Prats, N., Marín, I., Meyer, K. R., Muñoz, M. I., Aguilera, M., Mateo, L., Attolini, C. S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.04.501681 · Cited by 7
CHEK2 knockout is a therapeutic target for TP53-mutated hepatocellular carcinoma
Chen, Y., Zhu, Z., Wu, X., Li, H., Guan, W., & Ren, H. (2024) · Cell Death Discovery · doi:10.1038/s41420-023-01777-4 · Cited by 6
Du, J., Bai, D., Gu, C., Zhao, J., Zhou, C., Wang, Y., Zhao, Y., & Lu, N. (2024) · Oncogene · doi:10.1038/s41388-024-03142-w · Cited by 6
Shen, Z., Wang, Y., Gao, J., Gu, W. L., Ren, Z., Xu, L., Qian, R., Miao, Q., Hu, X., Wu, Y., et al. (2025) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2025.112040 · Cited by 6
Epigenetic Regulation of Cellular Senescence in Gastrointestinal Cancer
Ye, T., Gao, H., Zhang, Z., Ge, Y., Liu, Y.-K., Yan, J.-Y., Li, D., Chen, F., & Song, H. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0949 · Cited by 6
Zhang, Z., Zhou, J., Huang, R., Zhuang, X., & Ni, S. (2025) · Discover Oncology · doi:10.1007/s12672-025-02182-2 · Cited by 6
Targeting cellular senescence as a therapeutic vulnerability in gastric cancer
Geng, H., Huang, C., Xu, L., Zhou, Y., Dong, Z., Zhong, Y., Li, Q., Yang, C. G., Huang, S., Liao, W., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122631 · Cited by 6
Chen, H., Liu, H., Zhang, X., Wang, S., Liu, C., An, K., Liu, R., & Tian, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1422033 · Cited by 7
Zhen, Z., Zhu, S., Jin, J., Wang, L., & Lu, W. P. (2020) · Analytica Chimica Acta · doi:10.1016/j.aca.2020.07.079 · Cited by 7
Self-citationWang, B., Zhang, Y., Qiuyun, Z., Zhiqiang, Z., Changyong, L., Wang, Z., Chen, B., Wang, Y., Ge, X., Ying, Q., et al. (2023) · PubMed Central · doi:10.19852/j.cnki.jtcm.20221013.001 · Cited by 6
Zeng, D., Yu, C., Chen, S., Zou, L., Chen, J., & Xu, L. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03364-y · Cited by 6
Mi, W., You, J., Li, L., Zhu, L., Xia, X., Yang, L., Li, F., Xu, Y., Bi, J., Liu, P., et al. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae016 · Cited by 8
Effects of Berberine on Liver Cancer
Liu, Y., Nwafor, E.-O., Li, Z., Wang, J., Feng, X., Li, H., Jia, B., Ma, H., He, J., Pi, J., et al. (2022) · Natural Product Communications · doi:10.1177/1934578x221102032 · Cited by 7
Cellular senescence in colorectal cancer: its occurrence, effect and therapy
Liang, Y., Wang, M., Wang, X., Yang, Z., Wang, S., Li, F., Su, L., & Yang, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1580951 · Cited by 5
Matrine in Liver Diseases: Mechanistic Insights and Therapeutic Potential
Wen, W., Xia, J., Liu, G., & Wang, C. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s577265 · Cited by 5
Self-citationRole of TRP Channels in Liver-Related Diseases
Liu, Y., Lyu, Y., Zhu, L., & Wang, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512509 · Cited by 5
Hua, Y., Cao, P., Wang, W., Chen, H., Hu, Z., Yang, S., Ge, Y., Heng Jun, G. A. O., Lin, F., & Wu, H. (2024) · ACS Materials Letters · doi:10.1021/acsmaterialslett.4c00058 · Cited by 5
Self-citationThe Genomic Landscape of Wilson Disease in a Pan India Disease Cohort and Population‐Scale Data
Kumar, M., Sharma, S., Pandey, S., Mammayil, G., Kuzhiyil, A. P., Sreesh, S., Arakkal, R., Radhakrishnan, D. M., Rajan, R., Amalnath, D. S., et al. (2024) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.14266 · Cited by 5
Okamura, K., Sato, M., Suzuki, T., & Nohara, K. (2024) · Environmental Health and Preventive Medicine · doi:10.1265/ehpm.24-00139 · Cited by 5
Drug Discovery in Liver Disease Using Kinome Profiling
Yu, B., Mamedov, R., Fuhler, G. M., & Peppelenbosch, M. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052623 · Cited by 5
Chang, X., Wang, J., & Ni, C. (2021) · ONCOLOGIE · doi:10.32604/oncologie.2021.014152 · Cited by 5
You, Y., Wang, Z., Huang, Z., Tang, X., Huang, X., & Li, W. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.119048 · Cited by 5
Multiple characteristic alterations and available therapeutic strategies of cellular senescence
Zhao, Y., Li, H., Guo, Q., & Hui, H. (2023) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200178 · Cited by 5
Chen, Y., Zhu, Z., Ma, T., Zhang, L., Chen, J., Jiang, J., Lu, C., Ding, Y., Guan, W., Yi, N., et al. (2023) · Smart Medicine · doi:10.1002/smmd.20230005 · Cited by 5
Effective sequential combined therapy with carboplatin and a CDC7 inhibitor in ovarian cancer
Li, J., Hu, H., He, J., Hu, Y., Liu, M., Cao, B., Chen, D., Ye, X., Zhang, J., Zhang, Z., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101825 · Cited by 4
Metadata
- Authors
- Wang, C., Vegna, S., Jin, H., Benedict, B., Lieftink, C., Ramirez, C., de Oliveira, R. L., Morris, B., Gadiot, J., Wang, W., du Chatinier, A., Wang, L., Gao, D., Evers, B., Jin, G., Xue, Z., Schepers, A., Jochems, F., Sanchez, A. M., Mainardi, S., te Riele, H., Beijersbergen, R. L., Qin, W., Akkari, L., & Bernards, R.
- Affiliations
- Shanghai Jiao Tong University (CN)
- The Netherlands Cancer Institute (NL)
- Fudan University (CN)
- Corresponding author
- Qin, Wenxin
- Akkari, Leila
- Bernards, René
- ORCID
- Venue
- Nature
- Published
- 2019-10-02
- Volume
- 574
- Issue
- 7777
- Pages
- 268-272
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC6858884
- OpenAlex
- W2977409903
- Cited by
- 427
- References
- 31
- Citations by year
- 2026: 29 · 2025: 51 · 2024: 85 · 2023: 64 · 2022: 66 · 2021: 67 · 2020: 63
- FWCI
- 33.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- hepatocellular carcinoma, liver cancer, senescence, senolysis, TP53 mutation, sertraline, mTOR signaling, apoptosis, drug combination therapy, kinome screen, antidepressant repurposing
- MeSH terms
- Animals, Disease Models, Animal, Female, Liver Neoplasms, Male, Mice, Inbred BALB C, Mutation, Signal Transduction, Tumor Suppressor Protein p53, Cellular Senescence, Apoptosis, Protein Serine-Threonine Kinases, Cell Cycle Proteins, Sertraline, Cell Line, Tumor, Mice, TOR Serine-Threonine Kinases, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
